Preliminary Results for the year ended 31 March 2020

Cambridge, UK - 22nd July 2020

Nuformix plc (LSE:NFX) (“Nuformix” or “the Group”), a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines to provide enhanced benefit, is pleased to announce its preliminary results for the year ended 31 March 2020.

Download News

Back to all News